|
|
|
Corporate Overview
Tragara Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California focused on the clinical and commercial development of proprietary drugs for the treatment of various cancers. Tragara launched operations in January 2007 and is focusing its development resources on two proprietary compounds: (1) Capoxigem® (apricoxib; TG01), an oral, potent, and selective inhibitor of cyclooxygenase-2 (COX-2) for the treatment of solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer and (2) TG02- multikinase inhibitor for the treatment of hematologic and solid tumors.
Tragara is managed by a team of entrepreneurs with both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. |
|
|
